Propanc Biopharma (PPCB) Stock: Buy, Sell, or Hold?
PPCB - Propanc Biopharma, Inc. Common Stock
$0.51
-0.02 (-4.39%)
▼
5d:
-21.66%
30d:
-62.22%
90d:
-66.0%
WAIT
LOW Confidence
Analysis Updated: Sep 29, 2026 12:00 AM ET
Earnings: Oct 05, 2026
5d
Get Alerted When PPCB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PPCB is down 21.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PPCB is down 21.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PPCB is currently trading at $0.51, which is considered oversold relative to its 30-day fair value range of $0.62 to $1.30.
Technical Outlook: Technically, PPCB is in a downtrend. The price is currently testing key support at $0.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1.52 (+185.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PPCB is in a downtrend. The price is currently testing key support at $0.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1.52 (+185.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.62 -
$1.30
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 185.0% below Wall St target ($1.52)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.62 -
$1.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.52
Resistance Level
$0.88
Current Trend
Downtrend
Technical data as of
Sep 28, 2026
Fundamental Context
Wall Street Target
$1.52
(+185.0%)
Share & Embed Analysis
Last updated: September 29, 2026 12:57 PM ET
Data refreshes hourly during market hours. Next update: 1:57 PM
Data refreshes hourly during market hours. Next update: 1:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PPCB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 48 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 54 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 56 HOLD |